Background Ibandronate (Bonviva®) is effective in the treatment of postmenopausal women with osteoporosis. But, there were few datas about Ibandronate (Bonviva®) treatment in Korea. We evaluated the effect of Ibandronate (Bonviva®) therapy on bone mass and compared the effectivity on bone mineral density (BMD) in 1-year treatment group
Objectives The aim of the study is to assess the effect of 1-year treatment with Ibandronate (Bonviva®) on bone mineral density (BMD) in postmenopausal women with osteopenia or osteoporosis.
Methods The BMD was assessed in 118 postmenopausal women with osteopenia or osteoporosis from March 2007 to January 2011, 42 patents who treated with 2.5 mg per day of Ibandronate (Bonviva®) were enrolled to study. BMD of lumbar spine (L2-L4) and femur was assessed by dual energy absortiometry at baseline, 12 months after treatment.
Results The annual BMD of the lumbar spine showed a 9.11% increase, while also positive changes were noted in the proximal femur as a 1.89% increase. The BMD changes were 11% (L: Lumbar spine) and 1.1% (F: Femur) for the T-scores <-4.0, 6.3% (L) and 0.9% (F) for the T-scores -3.0∼-4.0, and 3.8% (L) and 0.5% (F) for the T-scores >-3.0 respectively.
Conclusions This study suggests that Ibandronate (Bonviva®) treatment in postmenopausal women with osteopenia or osteoposis is effective in terms of improving BMD.
Llewellyn-Jones D. Osteoporosis. In: Burger H, Boulet M editors. A portrait of the menopause: expert reports on medical and therapeutic strategies for the 1990s. Lancs: The Parthenon Publishing Group 83–103, 1991.
Kanis JA, Melton LJ III, Chistiansen C, Johnston CC, KhaltaevN. The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141, 1994.
Disclosure of Interest None declared